How Medications Work in Your Body: Absorption, Metabolism & Effects

Understanding pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body) empowers safer, more effective medication use. This knowledge helps you partner with your prescriber and pharmacist.

Pharmacokinetics (ADME)

1. Absorption

Drug entry into systemic circulation.

  • Routes: Oral (GI tract), IV (direct), SC/IM, transdermal, inhalational, sublingual/buccal, rectal
  • Oral factors: Solubility, permeability, first-pass metabolism, food effects (↑/↓ absorption), gastric pH, motility, efflux transporters (P-gp)
  • Bioavailability (F): Fraction reaching circulation unchanged. IV = 100%. Oral often <100%.

2. Distribution

Transport from blood to tissues.

  • Volume of distribution (Vd): Theoretical volume drug appears to occupy. High Vd = extensive tissue binding.
  • Protein binding: Albumin, α1-acid glycoprotein. Only free (unbound) drug is pharmacologically active.
  • Blood-brain barrier: Restricts CNS entry; relevant for neurologic/psychiatric drugs
  • Placental transfer: Critical in pregnancy

3. Metabolism (Biotransformation)

Chemical modification, primarily in liver, to increase polarity for excretion.

  • Phase I: Oxidation, reduction, hydrolysis (CYPs: 3A4, 2D6, 2C9, 2C19, 1A2). Creates active/inactive/toxic metabolites.
  • Phase II: Conjugation (glucuronidation, sulfation, methylation). Usually inactive, renally excreted.
  • Genetic polymorphism: CYP2D6, 2C19, TPMT, UGT1A1 → poor/ultrarapid metabolizers
  • Drug interactions: Induction (↑ metabolism, ↓ levels) vs. inhibition (↓ metabolism, ↑ toxicity)

4. Excretion

Elimination from body.

  • Renal: Glomerular filtration, tubular secretion, reabsorption. Dose adjust in CKD.
  • Biliary/fecal: For high MW, protein-bound drugs; enterohepatic recirculation possible
  • Pulmonary: Volatile anesthetics, alcohol
  • Clearance (CL): Volume of blood cleared per unit time. Half-life (t½) = 0.693 × Vd / CL

Pharmacodynamics

Drug effect at site of action.

  • Receptor binding: Agonist (activates), antagonist (blocks), partial agonist, inverse agonist
  • Enzyme inhibition/activation
  • Ion channel modulation
  • Transporter effects
  • Dose-response: EC50, Emax, therapeutic window
  • Tolerance, tachyphylaxis, sensitization

Key Concepts for Patients

  • Steady state: ~5 half-lives with regular dosing
  • Loading dose: Rapidly achieve target concentration
  • Therapeutic drug monitoring (TDM): For narrow therapeutic index drugs (warfarin, lithium, vancomycin, some biologics)
  • Adherence: Missed doses → subtherapeutic levels; doubling up → toxicity
  • Food/drug/supplement interactions: Always disclose all substances

Side Effects and Safety

  • On-target: Exaggerated therapeutic effect (e.g., hypoglycemia on insulin)
  • Off-target: Unrelated receptor effects (e.g., antihistamine sedation)
  • Idiosyncratic: Unpredictable, often immune-mediated (DRESS, SJS/TEN)
  • Reporting: FDA MedWatch, your pharmacist, prescriber

Your pharmacist is the medication expert on your team. Consult them for interaction checks, administration guidance, and cost-saving alternatives.

Prescription Medications - Related Articles